Spanish pharmaceutical company Almirall S.A. (BME:ALM) on Friday reported positive long-term interim results from the Phase 3b ADlong study evaluating lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis.

Data showed that 94% of patients achieved meaningful skin improvement (EASI-75), 75% reached near-complete skin clearance (EASI-90), and 78% experienced meaningful itch relief (Pruritus NRS ≤4) with up to four years of treatment.

The majority of patients maintained these outcomes on lebrikizumab monotherapy, with 80% achieving results without topical corticosteroids and 80% maintaining benefits on monthly dosing. The safety profile remained consistent with prior findings, with no new safety signals and most adverse events classified as mild or moderate, including nasopharyngitis, upper respiratory tract infections, and conjunctivitis, and not leading to discontinuation.

Almirall highlighted the results alongside more than 15 scientific presentations across dermatology indications at the American Academy of Dermatology Annual Meeting, reinforcing its focus on medical dermatology. The ADlong study remains ongoing, with an additional year of treatment planned to further evaluate long-term outcomes.

Almirall has licensed the rights to develop and commercialise lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe, while Eli Lilly and Company (NYSE:LLY) retains rights for development and commercialisation in the United States and the rest of the world outside Europe.